SHLT vs. TOI, PTWO, HYPR, MURA, SEPA, IKNA, MGRM, AEON, VNRX, and NVNO
Should you be buying SHL Telemedicine stock or one of its competitors? The main competitors of SHL Telemedicine include Oncology Institute (TOI), Pono Capital Two (PTWO), Hyperfine (HYPR), Mural Oncology (MURA), SEP Acquisition (SEPA), Ikena Oncology (IKNA), Monogram Orthopaedics (MGRM), AEON Biopharma (AEON), VolitionRx (VNRX), and enVVeno Medical (NVNO). These companies are all part of the "medical" sector.
SHL Telemedicine (NASDAQ:SHLT) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, community ranking, dividends, risk, analyst recommendations and institutional ownership.
SHL Telemedicine has a net margin of 0.00% compared to Oncology Institute's net margin of -20.28%. SHL Telemedicine's return on equity of 0.00% beat Oncology Institute's return on equity.
20.1% of SHL Telemedicine shares are held by institutional investors. Comparatively, 36.9% of Oncology Institute shares are held by institutional investors. 9.5% of Oncology Institute shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Oncology Institute received 3 more outperform votes than SHL Telemedicine when rated by MarketBeat users. However, 100.00% of users gave SHL Telemedicine an outperform vote while only 66.67% of users gave Oncology Institute an outperform vote.
SHL Telemedicine has higher earnings, but lower revenue than Oncology Institute.
In the previous week, Oncology Institute had 11 more articles in the media than SHL Telemedicine. MarketBeat recorded 15 mentions for Oncology Institute and 4 mentions for SHL Telemedicine. SHL Telemedicine's average media sentiment score of 0.29 beat Oncology Institute's score of -0.58 indicating that SHL Telemedicine is being referred to more favorably in the media.
SHL Telemedicine presently has a consensus price target of $11.00, suggesting a potential upside of 77.99%. Oncology Institute has a consensus price target of $2.25, suggesting a potential upside of 276.70%. Given Oncology Institute's higher probable upside, analysts plainly believe Oncology Institute is more favorable than SHL Telemedicine.
Summary
SHL Telemedicine beats Oncology Institute on 7 of the 13 factors compared between the two stocks.
Get SHL Telemedicine News Delivered to You Automatically
Sign up to receive the latest news and ratings for SHLT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SHLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SHL Telemedicine Competitors List
Related Companies and Tools
